109 related articles for article (PubMed ID: 16439867)
21. Utility of week-4 viral response to tailor treatment duration in hepatitis C virus genotype 3/HIV co-infected patients.
Crespo M; Esteban JI; Ribera E; Falco V; Sauleda S; Buti M; Esteban R; Guardia J; Ocaña I; Pahissa A
AIDS; 2007 Feb; 21(4):477-81. PubMed ID: 17301566
[TBL] [Abstract][Full Text] [Related]
22. Scientific rationale and study design of the individualized dosing efficacy vs flat dosing to assess optimal pegylated interferon therapy (IDEAL) trial: determining optimal dosing in patients with genotype 1 chronic hepatitis C.
McHutchison J; Sulkowski M
J Viral Hepat; 2008 Jul; 15(7):475-81. PubMed ID: 18363672
[TBL] [Abstract][Full Text] [Related]
23. Pilot study of low-dose interleukin-2, pegylated interferon-alpha 2b, and ribavirin for the treatment of hepatitis C virus infection in patients with HIV infection.
Glesby MJ; Bassett R; Alston-Smith B; Fichtenbaum C; Jacobson EL; Brass C; Owens S; Sulkowski M; Race EM; Sherman KE;
J Infect Dis; 2005 Mar; 191(5):686-93. PubMed ID: 15688281
[TBL] [Abstract][Full Text] [Related]
24. Role of rapid virological response in prediction of sustained virological response to Peg-IFN plus ribavirin in HCV / HIV co-infected individuals.
Shea DO; Tuite H; Farrell G; Codd M; Mulcahy F; Norris S; Bergin C
J Viral Hepat; 2008 Jul; 15(7):482-9. PubMed ID: 18221297
[TBL] [Abstract][Full Text] [Related]
25. Comparison of low-dose pegylated interferon versus standard high-dose pegylated interferon in combination with ribavirin in patients with chronic hepatitis C with genotype 3: an Indian experience.
Sood A; Midha V; Hissar S; Kumar M; Suneetha PV; Bansal M; Sood N; Sakhuja P; Sarin SK
J Gastroenterol Hepatol; 2008 Feb; 23(2):203-7. PubMed ID: 17645472
[TBL] [Abstract][Full Text] [Related]
26. CD4 T lymphocyte proliferative responses to hepatitis C virus (HCV) antigens in patients coinfected with HCV and human immunodeficiency virus who responded to anti-HCV treatment.
Legrand E; Neau D; Galperine T; Trimoulet P; Moreau JF; Pitard V; Lacut JY; Ragnaud JM; Dupon M; Le Bail B; Bernard N; Schvoerer E; Houghton M; Fleury H; Lafon ME
J Infect Dis; 2002 Aug; 186(3):302-11. PubMed ID: 12134226
[TBL] [Abstract][Full Text] [Related]
27. IgE antibodies to hepatitis C virus core and nonstructural antigens in chronic hepatitis C patients before and after antiviral treatment.
Silva JPCG; Jesus LS; Isabel Schinoni M; Oliveira IS; Atta MLBS; Atta AM
Int Immunopharmacol; 2021 Apr; 93():107405. PubMed ID: 33529909
[TBL] [Abstract][Full Text] [Related]
28. Involvement of the Interleukin-23/Interleukin-17 Axis in Chronic Hepatitis C Virus Infection and Its Treatment Responses.
Meng P; Zhao S; Niu X; Fu N; Su S; Wang R; Zhang Y; Qiao L; Nan Y
Int J Mol Sci; 2016 Jul; 17(7):. PubMed ID: 27428948
[TBL] [Abstract][Full Text] [Related]
29. CD127 expression, exhaustion status and antigen specific proliferation predict sustained virologic response to IFN in HCV/HIV co-infected individuals.
Kared H; Saeed S; Klein MB; Shoukry NH
PLoS One; 2014; 9(7):e101441. PubMed ID: 25007250
[TBL] [Abstract][Full Text] [Related]
30. Acute and chronic immune biomarker changes during interferon/ribavirin treatment in HIV/HCV co-infected patients.
Jain MK; Adams-Huet B; Terekhova D; Kushner LE; Bedimo R; Li X; Holodniy M
J Viral Hepat; 2015 Jan; 22(1):25-36. PubMed ID: 24506344
[TBL] [Abstract][Full Text] [Related]
31. Decreased frequencies of virus-specific T helper type 1 cells during interferon alpha plus ribavirin treatment in HIV-hepatitis C virus co-infection.
Alatrakchi N; Di Martino V; Thibault V; Benhamou Y; Katlama C; Poynard T; Autran B
AIDS; 2004 Jan; 18(1):121-3. PubMed ID: 15090839
[TBL] [Abstract][Full Text] [Related]
32. Characterisation of the cytokine milieu associated with the up-regulation of IL-6 and suppressor of cytokine 3 in chronic hepatitis C treatment non-responders.
Martinez D; Palmer C; Simar D; Cameron BA; Nguyen N; Aggarwal V; Lloyd AR; Zekry A
Liver Int; 2015 Feb; 35(2):463-72. PubMed ID: 24461080
[TBL] [Abstract][Full Text] [Related]
33. Expansion of CD56- NK cells in chronic HCV/HIV-1 co-infection: reversion by antiviral treatment with pegylated IFNalpha and ribavirin.
Gonzalez VD; Falconer K; Michaëlsson J; Moll M; Reichard O; Alaeus A; Sandberg JK
Clin Immunol; 2008 Jul; 128(1):46-56. PubMed ID: 18495540
[TBL] [Abstract][Full Text] [Related]
34. Immune response of Th17-associated cytokines by peripheral blood mononuclear cells from patients with chronic hepatitis C virus infection.
Cabral MS; Santos TPS; Santos PL; Schinoni MI; Oliveira IS; Pereira AB; Atta AM; Sousa-Atta MLB
Cytokine; 2018 Feb; 102():200-205. PubMed ID: 28969940
[TBL] [Abstract][Full Text] [Related]
35. Interferon-gamma: biologic functions and HCV terapy (type I/II) (2 of 2 parts).
Gattoni A; Parlato A; Vangieri B; Bresciani M; Derna R
Clin Ter; 2006; 157(5):457-68. PubMed ID: 17147054
[TBL] [Abstract][Full Text] [Related]
36. Quantitative analysis of specific Th1/Th2 helper cell responses and IgG subtype antibodies in interferon-alpha-treated patients with chronic hepatitis C.
Hempel G; Galle PR; Löhr HF
J Med Virol; 2001 Jul; 64(3):340-9. PubMed ID: 11424124
[TBL] [Abstract][Full Text] [Related]
37. Inteleukin-23 promotes interferon-α responsiveness in hepatitis C virus/HIV-coinfected patients.
Odigie M; Osinusi A; Barrett L; Townsend K; Wang H; Suffredini AF; Masur H; Polis MA; Kottilil S
AIDS Res Hum Retroviruses; 2014 Aug; 30(8):775-82. PubMed ID: 24856902
[TBL] [Abstract][Full Text] [Related]
38. Decreased IFNγ production correlates with diminished production of cytokines by dendritic cells in patients infected with hepatitis C virus and receiving therapy.
Hammond T; Lee S; Watson MW; Flexman JP; Cheng W; Price P
J Viral Hepat; 2011 Jul; 18(7):482-92. PubMed ID: 20529204
[TBL] [Abstract][Full Text] [Related]
39. Maintenance of Th1 hepatitis C virus (HCV)-specific responses in individuals with acute HCV who achieve sustained virological clearance after treatment.
Flynn JK; Dore GJ; Hellard M; Yeung B; Rawlinson WD; White PA; Kaldor JM; Lloyd AR; Ffrench RA;
J Gastroenterol Hepatol; 2013 Nov; 28(11):1770-81. PubMed ID: 23663030
[TBL] [Abstract][Full Text] [Related]
40. Induction of IL-1Ra in resistant and responsive hepatitis C patients following treatment with IFN-con1.
Cotler SJ; Craft T; Ferris M; Morrisey M; McCone J; Reddy KR; Conrad A; Jensen DM; Albrecht J; Taylor MW
J Interferon Cytokine Res; 2002 May; 22(5):549-54. PubMed ID: 12060493
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
